Fast Track Designation

Mechanism

Related News

Zentalis selects 400 mg azenosertib regimen for Cyclin E1-positive ovarian cancer

Apr 18, 2026

Zentalis selected a 400 mg once-daily, 5-days-on/2-days-off azenosertib regimen for Cyclin E1-positive platinum-resistant ovarian cancer after a DENALI Phase 2 interim analysis. The regimen is planned for DENALI and ASPENOVA as the company pursues a potential accelerated approval pathway.

Adagene and Incyte Launch Clinical Collaboration for Muzastotug Combination in Colorectal Cancer

Apr 02, 2026

Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.